Skip to main content

Table 1 Patient characteristics of training and validation cohort

From: Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer

   Training cohort (N = 67) Validation cohort (N = 34) P-value
Age   59.5 ± 11.6 62.5 ± 11.4 0.22a
Sex Male 54 (80.6%) 22 (64.7%) 0.13b
Female 13 (19.4%) 12 (35.3%)  
Clinical T stage cT1–3 59 (88.1%) 30 (88.2%) 1.00b
cT4 8 (11.9%) 4 (11.8%)  
Clinical N stage cN0 9 (13.4%) 5 (14.7%) 1.00b
cN1–2 58 (86.6%) 29 (85.3%)  
Dworak TRG 1 15 (22.4%) 4 (11.8%) 0.64b
2 27 (40.3%) 16 (47.1%)  
3 14 (20.9%) 8 (23.5%)  
4 11 (16.4%) 6 (17.6%)  
Pathologic T stage ypT0–2 37 (55.2%) 16 (47.1%) 0.57b
ypT3–4 30 (44.8%) 18 (52.9%)  
Pathologic N stage ypN0 46 (68.7%) 22 (64.7%) 0.86b
ypN1–2 21 (31.3%) 12 (35.3%)  
Initial CEA ≤5 ng/mL 42 (62.7%) 24 (70.6%) 0.57b
> 5 ng/mL 25 (37.3%) 10 (29.4%)  
Local recurrence Yes 8 (11.9%) 2 (5.9%) 0.54b
No 59 (88.1%) 32 (94.1%)  
Distant metastasis Yes 16 (23.9%) 6 (17.6%) 0.64b
No 51 (76.1%) 28 (82.4%)  
  1. aStudent’s t-test
  2. bChi-squared test
  3. Abbreviations: TRG tumor regression grade, CEA carcinoembryonic antigen